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Drug-resistant tuberculosis (DR-TB) is caused 
by Mycobacterium tuberculosis (MTB) with 
demonstrated resistance to first-line and/or second-
line TB drugs on laboratory drug-susceptibility testing 
(DST). The revised classification and definitions of 
DR-TB, according to the World Health Organization (WHO), are 
given in Table 1.[1] Rifampicin (RIF), one of the most potent first-
line TB drugs, results in sterilisation and has allowed the duration of 
TB treatment to be shortened to 6 months with low risk of subsequent 
relapse. Therefore, any RIF-resistant TB requires treatment with 
second-line TB drugs for 18 months - 2 years. Detection of resistance 
to RIF is an important indicator for more extensive resistance to 
other first-line drugs in countries where prevalence is high.[2] 
Approximately 1.8% of new TB cases and 6.7% of previously treated 
TB cases in SA are multidrug resistant (MDR).[2] MTB may acquire 
resistance to certain drugs through selective drug pressure from 
suboptimal treatment,[3] such as in situations where adherence is 
poor. However, the majority of new DR-TB cases diagnosed in SA are 
due to transmission of already resistant strains.[4] Unpublished data in 
annual reports from the Western Cape Department of Health indicate 
that half of all new DR-TB cases diagnosed each year have never 
received TB treatment. Significant scale-up of access to services, 
with widespread implementation of rapid diagnostic techniques and 
prompt initiation of effective treatment in all diagnosed patients, is 
required to reduce ongoing DR-TB transmission. Fig. 1 demonstrates 
a rising DR-TB case detection, with a widening gap between those 
diagnosed and those treated in SA in recent years.[2] The National 
Department of Health has addressed this by endorsing a policy 
of decentralisation of DR-TB services to allow MDR treatment 
initiation at designated decentralised units across the country.[5] With 
appropriate training and support this is also feasible at a primary care 
level, as demonstrated in Khayelitsha, Western Cape Province.[6] 
Detection of drug-resistant tuberculosis (DR-TB) increases each year in South Africa (SA). Most cases result from airborne transmission 
of already resistant TB strains. Epidemic control relies on rapid diagnosis and initiation of effective treatment to reduce the period of 
infectiousness and ongoing transmission. 
The rapid diagnostic test, Xpert MTB/RIF, has replaced smear microscopy for routine screening of all cases of presumptive TB in SA. 
Xpert also detects rifampicin (RIF) resistance, an indicator of more extensive drug resistance, allowing rapid initiation of effective second-
line treatment. Definitive diagnosis of DR-TB relies on laboratory confirmation of MTB, along with drug-susceptibility testing (DST) using 
culture-based (phenotypic) and/or molecular (genotypic) techniques.
A standardised treatment regimen, consisting of five (or six) drugs (pyrazinamide, (ethambutol), kanamycin, moxifloxacin, ethionamide, 
terizidone), is offered to individuals following initial diagnosis of RIF resistance. Treatment regimens are individualised if and when 
molecular mutation details and second-line DST results indicate more extensive second-line drug resistance.
DR-TB treatment outcomes are poor owing to death, and interruption and failure of current treatment. Reliable access to newer, more 
effective drugs within shorter, more tolerable regimens is desperately needed to improve the chance of a cure for DR-TB patients.  
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Table 1. Categories of drug-resistant tuberculosis (DR-TB) – modified from the World Health Organization classification[1]
Category Definition
Monodrug-resistant TB Resistance to one first-line anti-TB drug only
Polydrug-resistant TB Resistance to more than one first-line anti-TB drug (other than both isoniazid and rifampicin)
Rifampicin-resistant TB Resistance to rifampicin detected using phenotypic or genotypic methods, with or without 
resistance to other anti-TB drugs, including resistance to rifampicin, whether monodrug-,   
multidrug-, polydrug- or extensively drug resistant
MDR-TB Resistance to at least both isoniazid and rifampicin
XDR-TB Resistance to any fluoroquinolone and to at least one of three second-line injectable drugs 
(capreomycin, kanamycin and amikacin), in addition to MDR
Pre-XDR MDR plus resistance to either a fluoroquinolone or a second-line injectable drug
MDR-TB = multidrug-resistant TB; XDR-TB = extensively drug-resistant TB.
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Diagnosis of DR-TB 
Owing to the high prevalence of DR-TB 
in SA, all patients with presumptive TB 
should ideally be screened for at least RIF 
resistance at initial clinical presentation. The 
signs, symptoms and radiographic features 
are indistinguishable from those of drug-
sensitive TB and therefore phenotypic and/
or genotypic laboratory tests are required 
for definitive diagnosis. Table 2 gives an 
overview of the available diagnostic tests. 
Molecular (or genotypic) techniques 
based on nucleic acid amplification can 
simplify logistics and reduce laboratory 
workload and are now used routinely in SA 
for identification of MTB, as well as rapid 
detection of genetic mutations associated 
with resistance to selected drugs. Direct 
smear microscopy has largely been replaced 
by the Xpert MTB/RIF (Cepheid, Sunnyvale, 
USA) test for routine detection of MTB in 
SA, but smear is still useful in confirmed TB 
cases to monitor bacterial load and response 
to treatment in individuals who produce 
smear-positive sputum initially. Xpert MTB/
RIF, or GeneXpert (GXP), was endorsed by 
the WHO in 2010; this technique identifies 
MTB and RIF resistance associated with 
specific mutations in the rpoB gene through 
an automated real-time polymerase chain 
reaction (PCR) technique.[7] This cartridge-
based closed system reduces both the 
infectious risk to laboratory workers and the 
risk of PCR contamination. The test takes 
<2 hours and, although not quite point of 
care, may be used in any laboratory with 
trained personnel. Following the nation-
wide roll-out of Xpert instruments in 2011, 
the national TB guidelines recommend an 
algorithmic approach for using GXP in 
new cases of presumed TB.[8] As the GXP 
identifies genetic material, which includes 
non-viable mycobacteria, it is less reliable 
for diagnosis of active TB in patients who 
completed TB treatment recently or for 
monitoring those already on TB treatment.
Following the detection of RIF-resistant 
TB using GXP, further testing is necessary 
to confirm RIF resistance and allow for 
more extensive DST. Definitive diagnosis 
of MTB is still through growth (and 
subsequent molecular identification) of 
viable bacilli on solid or liquid culture 
media, but because of the variable and 
inherent slow growth of the mycobacteria it 
takes 6 weeks for the culture to be reported 
negative.[9] Genotypic tests, such as the 
GenoType MTBDRplus (Hain Lifescience, 
Nehren, Germany) line-probe assay (LPA), 
can be done directly on smear-positive 
samples to rapidly confirm MTB and 
detect resistance to RIF and/or isoniazid 
(INH), but a culture is still necessary in the 
large number of smear-negative TB cases 
(especially common with HIV co-infection) 
for the LPA to be carried out on the 
cultured isolate. While the specificity of the 
LPA is the same for detection of RIF and 
INH resistance (99%), sensitivity is higher for 
detection of RIF (97%) than INH resistance 
(90%).[10] Therefore, phenotypic DST should 
be carried out routinely for confirmation of 
INH susceptibility in cases reported as RIF 
Table 2. Summary of diagnostic tests for Mycobacterium tuberculosis and drug-susceptibility testing 
Test Time Organisms identified
DST
CommentRIF INH AG FQ EMB
Smear microscopy 1 - 2 d AAFB - - - - - Can be done in local laboratory
Culture ≤6 wk MTB - - - - - Cultured AAFB identified as 
MTB using LPA
Phenotypic (culture-based) DST ≤6 wk following 
initial culture 
(≤12 wk in total)
MTB ü ü ü ü ü Used routinely for AG and 
FQ following detection of RIF 
resistance on genotypic testing 
Only used for RIF, INH and 
EMB on request or in cases of 
discordance
MTBDRplus LPA 2 d (smear) MTB ü ü Directly on smear-positive 
specimen
≤6 wk (culture) MTB ü ü Done on cultured organism if 
smear negative
MTBDRsl LPA ≤6 wk (culture) MTB ü ü ü 
Xpert MTB/RIF 2 h MTB ü 
MTB = Mycobacterium tuberculosis; AAFB = acid- and alcohol-fast bacilli; DR = drug resistant; DST = drug-susceptibility testing; RIF = rifampicin; INH = isoniazid; AG = aminoglycosides; 
FQ = fluoroquinolones; EMB = ethambutol; LPA = line-probe assay. 
Other diagnostic methods such as lipoarabinomannan (LAM) and microscopic observation drug susceptibility (MODS) are not carried out routinely in South Africa and therefore not covered here.
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Fig. 1. Incidence of drug-resistant tuberculosis cases diagnosed and proportion started on treatment in 
South Africa, 2007 - 2012.[2]
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monoresistant on LPA. The majority of RIF 
resistance cases are due to a mutation in the 
rpoB gene, but the LPA reports resistance 
to INH based on mutations in two different 
genes, inhA and KatG. For INH there may be 
discrepancies between mutations detected 
on molecular testing and phenotypic DST.
[11] While mutations in the KatG gene are 
likely to confer high-level INH resistance, 
mutations in the inhA gene may confer 
lower-level resistance and be overcome by 
higher doses of INH (16 - 18 mg/kg).[12] 
Additionally, mutations in the inhA gene may 
also confer cross-resistance to ethionamide 
(Eto),[11] one of the main second-line drugs 
used in the standard treatment of MDR-TB. 
Second-line DST for amikacin and 
ofloxacin is carried out routinely for all RIF-
resistant samples using phenotypic culture-
based methods to determine the growth of 
MTB bacilli in the presence of individual 
drugs. These results only become available 
weeks or months following initiation of 
MDR treatment and should be actively 
followed up as detection of further resis-
tance represents extensively drug-resistant 
(XDR) or pre-XDR TB and necessitates 
modification of treatment. The GenoType 
MTBDRsl (Hain Lifescience, Nehren, 
Germany) rapidly detects mutations 
conferring resistance to second-line drugs 
(specifically fluoroquinolones, ethambutol 
(EMB) and the injectable agents); however, 
concerns over the sensitivity of the test, 
particularly for resistance to the injectables, 
have delayed implementation in the routine 
diagnostic algorithm and the test is undergoing 
further evaluation. 
Discordance between GXP, LPA and/or 
phenotypic test results is not uncommon, 
and may cause confusion and delay 
treatment initiation. This highlights the 
importance of sending a second sample 
for confirmation of positive GXP results, 
and ideally a third sample to be taken at 
treatment initiation for culture and DST 
to provide further confirmation in cases 
of initial discordance. In patients with 
discordant results, correlation with clinical 
findings is crucial and specialist consultation 
may be necessary to ensure that they receive 
the most appropriate treatment without 
adversely affecting their chance of cure, 
but simultaneously limiting exposure to 
unnecessary and toxic drugs.
Treatment of DR-TB 
All patients with an initial diagnosis of DR-TB 
in SA are offered a standardised treatment 
regimen, which may be individually tailored 
at a later stage if and when further DST 
results become available. The standard 
regimen is usually designed at a national or 
regional level based on drug resistance data 
from prevalence surveys in representative 
patient populations; the public health benefit 
of this approach is wider and there is more 
rapid access to effective treatment, which is 
not initially reliant on specialist knowledge 
or skills. Table 3 describes the step-wise 
approach to designing regimens from the five 
WHO categories of TB drugs.[3] The WHO 
recommends at least four possible effective 
drugs initially, with use of the injectable 
agent for a minimum of 8 months, and a 
total treatment duration of 20 months.[3] 
The standardised regimen in SA comprises 
at least five drugs (EMB is sometimes 
included depending on treatment history 
and local prevalence of EMB resistance): 
pyrazinamide/ethambutol/kanamycin/
moxifloxacin/ethionamide/terizidone.
Weight-based dosing, common side-
effects and recommended monitoring 
for each drug are given in Table 4. The 
current SA DR-TB guidelines advise at least 
6 months for the injectable phase, until 
4 months post-sputum culture conversion 
(date of first of two negative sputum 
cultures taken at least 30 days apart), with 
total treatment duration calculated up to 
at least 18 months from the date of culture 
conversion.[13]
Unfortunately, clinical outcomes 
remain poor in SA, with <45% of MDR-
TB cases reported as treatment success (cure 
or completion).[2] The current standard MDR 
regimen is toxic and lengthy, with potentially 
fewer than four possible effective drugs, 
Table 3. WHO-recommended grouping of anti-TB drugs and step-wise approach to regimen design
Step Drug group Drug
1.  Choose any available and potentially effective drugs 
from Group 1
First-line oral agents Rifampicin/rifabutin 
Isoniazid
Pyrazinamide
Ethambutol
2. Choose an injectable agent (if susceptible) Injectable agents Kanamycin
Amikacin
Capreomycin
3. Choose a higher-generation fluoroquinolone Fluoroquinolones Moxifloxacin
Levofloxacin
4.  Add ≥2 drugs until at least four likely effective drugs 
in regimen (DST is not reliable for these)
Oral bacteriostatic second-lineTB agents Ethionamide
Terizidone*/cycloserine
Para-aminosalicylic acid 
5.  Consider adding in consultation with specialist if four 
drugs from other groups are possibly not effective 
Anti-TB drugs with limited data on efficacy and/or long-
term safety in DR-TB (includes new agents)
Bedaquiline
Linezolid
Clofazimine
High-dose isoniazid
Amoxicillin/clavulanate
Imipenem/clavulanate
Meropenem/clavulanate
Clarithromycin
WHO = World Health Organization; DST = drug-susceptibility testing; DR-TB = drug-resistant tuberculosis.
Adapted from the Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-resistant Tuberculosis.[3]
*Terizidone is comprised of two molecules of cycloserine and one molecule of terephtalaldehyde. Pharmacologically, it is therefore regarded as being similar to cycloserine.
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and therefore should be optimised where 
possible. DST for pyrazinamide (PZA) 
and EMB is not carried out routinely 
owing to poor reliability of the available 
testing methods, but genotyping studies 
have estimated that roughly 50% of MDR 
strains in SA are susceptible to PZA and/
or EMB and therefore routine addition to 
the standard regimen may benefit half of 
all MDR cases.[14] Although generally well 
tolerated, these two drugs may be more 
easily discontinued if there are concerns 
over pill burden or poor tolerance as they are 
not relied on as being effective. Terizidone 
is used despite lack of good evidence for 
efficacy and no routine DST for this drug. 
The presence of mutations in the inhA gene 
potentially indicates cross-resistance to Eto. 
If INH mutation data are routinely reported, 
clinicians could modify the regimen 
to remove Eto and add higher doses of 
INH (16 - 18 mg/kg) in cases with inhA 
mutations only. An algorithmic approach 
has been implemented in the Western Cape, 
whereby patients with GXP RIF-resistant 
TB are routinely offered a 7-drug regimen, 
which is later modified to withdraw one 
or more drugs according to information 
subsequently obtained from LPA results 
(Fig. 2). In a minority of situations where 
both inhA and KatG mutations are present 
(precluding use of either Eto or high-
dose INH), an alternative agent, such as 
clofazimine or para-aminosalicylate, is 
considered for addition to the regimen to 
ensure a minimum of four effective drugs. 
Furthermore, if any of the four presumed 
effective drugs in the standard regimen are 
contraindicated or later withdrawn (owing 
to adverse events or poor tolerance), an 
alternative agent should be considered for 
substitution, provided it is not added in 
isolation to a failing regimen. 
As 10% of MDR cases in SA are XDR,[2] 
initial treatment with standard MDR 
regimens may contribute to the development 
of amplified drug resistance owing to the 
selective pressure of treatment with only one 
or two effective drugs.[15] Until rapid second-
line diagnostics are routinely available for 
immediate detection of pre-XDR and XDR, 
it is crucial that phenotypic second-line DST 
results are followed up after initiation of 
standard MDR treatment to allow regimens 
to be modified as soon as possible according 
to the full resistance pattern and to improve 
the individual’s chance of cure. Furthermore, 
patients with MDR-TB, in whom standard 
treatment is failing (clinical deterioration, 
delayed sputum culture conversion, or 
reconversion to positive), the regimen should 
ideally be strengthened in consultation 
with an experienced clinician. Treatment 
options for individualised regimens in 
cases of pre-XDR, XDR-TB or MDR failure 
are severely limited and access to specific 
drugs is often, but not always, restricted 
to specialist hospital settings. With current 
XDR treatment success rates of <20%,[2] 
Table 4. Drugs used in the standard treatment of multidrug-resistant tuberculosis (MDR-TB) in South Africa
Drug (average daily dose, mg/kg)
Dosing by weight (all once daily)
Common side-effects Monitoring requiredWeight, kg Dose, mg
Pyrazinamide (20 - 30)  <33  By weight Hyperuricaemia, arthralgia, 
hepatotoxicity, rash, 
photosensitivity
Monthly transaminases, uric 
acid if clinically indicated33 - 50  1 000 - 1 500 
51 - 70  1 500 - 2 000 
>70  2 000
Ethambutol (15 - 20)  <33  By weight Retrobulbar neuritis Baseline and monthly 
visual acuity and colour 
discrimination monitoring, 
especially in renal failure
33 - 50  800  - 1 000 
51 - 70  1 000  - 1 200 
>70  1 200 
Kanamycin (15) <33  By weight Nephrotoxicity, ototoxicity, 
electrolyte disturbance
Baseline and monthly 
audiometry screen; and 
monthly serum creatinine 
clearance and potassium (K+) 
during injectable phase
33 - 50  500  - 750 
51 - 70  1 000 
>70  1 000 
Moxifloxacin (400 mg, fixed dose) <33  400  Nausea, diarrhoea, headache, 
dizziness, arthralgia, QT interval 
prolongation, hypo/hyper-
glycaemia
Symptomatic monitoring
33 - 50  400 
51 - 70  400 
>70  400 
Terizidone (15 - 20)  <33  By weight Central nervous system toxicity 
(poor concentration, lethargy, 
seizure, depression, psychosis), 
peripheral neuropathy, skin 
changes
Symptomatic monitoring
33 - 50  750 
51 - 70  750 
>70  750 
Ethionamide (15 - 20)  <33  By weight Nausea, vomiting, anorexia, 
metallic taste, hepatotoxicity, 
neurotoxicity, gynaecomastia, 
hair loss, impotence, acne, 
menstrual irregularity, 
hypothyroidism
Liver function tests every 
month
Thyroid-stimulating 
hormone at baseline and 
every 6 months
33 - 50  500 
51 - 70  750 
>70  750 
Adapted from the Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-resistant Tuberculosis [3] and the South African Department of Health Multi-drug 
Resistant Tuberculosis: A Policy Framework on Decentralised and Deinstitutionalised Management for South Africa.[5] 
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Send two sputum samples to lab – one sputum sample rst tested by GXP
(Second sputum sample tested for conrmation by smear, culture, LPA/DST)
Patient recalled or returns to clinic for result
Send third sputum sample (baseline) for another smear, culture, LPA/DST on same day
Start MDR-TB treatment based on GXP result
GXP positive RIF resistant
hdINH (15 mg/kg)/PZA/EMB/Kana/Mfx/Trd/Eto
Receive smear/culture result with LPA conrmation of RIF/INH resistance and mutation details
KatG only
Drop hdINH
RIF-mono
Continue regimen
Conrm INH result
(phenotypic DST)
inhA only
Drop Eto
KatG and inhA
Drop Eto + hdINH
Refer to tertiary
centre for advice on
regimen
hdINH/PZA/EMB/Kana/Mfx/Trd
-     If INH resistant, drop hdINH
      PZA/EMB/Kana/Mfx/Trd/Eto
-     If INH susceptible, drop Eto and
      reduce to normal dose INH
      PZA/EMB/INH/Kana/Mfx/Trd
Follow up second-line DST results
for injectable (Ami) and uoroquinolone (Ofx/Mfx) resistance
If any second-line resistance (pre-XDR or XDR) detected
refer to specialist centre for individualised regimen
PZA/EMB/Kana/Mfx/Trd/Eto
Fig. 2. Western Cape algorithm for management of patients diagnosed with GXP rifampicin-resistant tuberculosis and treatment modification according to 
information on isoniazid mutations. (GXP = GeneXpert; RIF = rifampicin; LPA = line-probe assay; DST = drug-susceptibilty testing; MDR-TB = multidrug-
resistant tuberculosis; PZA = pyrazinamide; EMB = ethambutol; Kana = kanamycin; Mfx = moxifloxacin; Eto = ethionamide; Trd = terizidone; 
Ofx = ofloxacin; hdINH = high-dose isoniazid.)
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there is little point reserving drugs for salvage regimens at a later 
stage, and the most likely effective drugs should be offered as soon 
as possible. 
There are a number of new TB drugs in the late phases of clinical 
development, such as bedaquiline (BDQ), delaminid and PA-824, 
and combinations of new and repurposed drugs (e.g. linezolid) 
are being compared with existing drugs in clinical trials to provide 
shorter, more effective and more tolerable regimens for DR-TB.[16] 
While awaiting the results of these trials, efforts are being made 
to increase access to new drugs for DR-TB patients with severely 
limited treatment options. The WHO issued interim guidance for 
use of BDQ for treating MDR-TB in June 2013 and the SA Medicines 
Control Council (MCC) has recently registered the drug for use 
outside of clinical trials. The MCC-approved national BDQ Clinical 
Access Programme has allowed access to the drug since 2013 – within 
optimised regimens for patients with pre-XDR and XDR-TB.[17] The 
experience gained from the programme will inform wider use of 
BDQ for other DR-TB patients once the drug is routinely available. 
Summary
Case detection of DR-TB in SA has increased following nationwide 
roll-out of Xpert MTB/RIF. However, this may have limited impact 
on ongoing transmission of the disease unless the majority of cases 
rapidly initiate effective treatment. While an initial standardised 
treatment regimen may be more easily implemented at decentralised 
treatment initiation sites, the current MDR regimen should be 
optimised as soon as second-line susceptibility results are obtained 
to prevent acquisition of further resistance. Pre-XDR, XDR and 
MDR failure cases require early individualised treatment with all 
available, potentially effective drugs; however, treatment options 
remain severely limited. New and repurposed drugs may be made 
available for these cases through the national treatment programme 
within the framework of expert guidance while awaiting results of 
clinical trials for shorter, more effective and more tolerable regimens 
for all patients with DR-TB. 
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